Navigation Links
Omeros Announces Closing of $34.5 Million Public Offering of Common Stock
Date:7/2/2012

SEATTLE, July 2, 2012 /PRNewswire/ -- Omeros Corporation (NASDAQ: OMER) today announced that it has closed the underwritten public offering that was priced and allocated to investors prior to the opening of the market on June 27, 2012, relating to the sale of 3,365,854 shares of its common stock at a price of $10.25 per share for gross proceeds of approximately $34.5 million. The closing included the sale of 439,024 shares of common stock sold pursuant to the overallotment option granted by Omeros to the underwriters, which the underwriters exercised in full. After deducting underwriting discounts and other estimated offering expenses, Omeros will receive net proceeds from the transaction of approximately $32.3 million.

Omeros intends to use the net proceeds of the offering for general corporate purposes, including expenses related to the clinical development of Omeros' two ongoing Phase 3 clinical development programs – OMS302 for use during intraocular lens replacement procedures and OMS103HP for use during arthroscopic partial meniscectomy surgery. The net offering proceeds may also be used to fund research and development in Omeros' preclinical studies and clinical trials, capital expenditures, working capital and to otherwise advance Omeros' product candidates toward commercialization.

Cowen and Company, LLC and Deutsche Bank Securities Inc. acted as the joint book-running managers for the offering, Canaccord Genuity Inc. and Wedbush PacGrow Life Sciences acted as co-managers, and WBB Securities served as a financial advisor to Omeros.

A shelf registration statement (File No. 333-169856) relating to these securities was filed with the Securities and Exchange Commission on October 8, 2010 and declared effective on October 18, 2010. A final prospectus supplement related to the offering was filed with the Securities and Exchange Commission on June 28, 2012. The securities may be offered only by means of a prospectus, including the final prospectus supplement, forming a part of the effective registration statement. Copies of the final prospectus supplement and accompanying prospectus relating to the offering may be obtained from Cowen and Company, LLC (c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, Phone: 631-274-2806, Fax: 631-254-7140), or Deutsche Bank Securities Inc., Attn: Prospectus Group, 60 Wall Street, New York, NY 10005-2836 or by telephone at: (800) 503-4611, or by email at: prospectus.CPDG@db.com. An electronic copy of the prospectus supplement and accompanying prospectus relating to the offering is available on the website of the Securities and Exchange Commission at www.sec.gov.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities of Omeros, and shall not constitute an offer, solicitation or sale of any security in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. 

About Omeros Corporation
Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, coagulopathies and disorders of the central nervous system.

Forward-looking Statements
This press release contains forward-looking statements as defined within the Private Securities Litigation Reform Act of 1995, which are subject to the "safe harbor" created by those sections. These statements include, but are not limited to, statements regarding Omeros' expectations regarding the underwritten public offering. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Omeros' actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors described under the heading "Risk Factors" in the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 10, 2012. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and the Company assumes no obligation to update these forward-looking statements publicly, even if new information becomes available in the future.


'/>"/>
SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Omeros Prices $30 Million Public Offering of Common Stock
2. Omeros Announces Proposed Public Offering of Common Stock
3. Omeros to Present at Jefferies 2012 Global Healthcare Conference
4. Omeros Adds Four More Unlocked Orphan GPCRs to its Portfolio
5. Omeros to Present at Deutsche Bank Securities Health Care Conference
6. Amylin Pharmaceuticals, Inc. Shareholder Alert: Bernstein Liebhard LLP Announces Investigation Of Acquisition By Bristol-Myers Squibb Company
7. MicroVention Announces First Patient Enrollment In Clinical Trial To Compare Coiling Technologies For Treating Brain Aneurysms
8. Omron Healthcare Announces New Pedometers
9. Improved Maintenance and Control of Electronic Health Records. ICAP Patent Brokerage Announces for Auction Patented Techniques for Improved Patient Control and Selective Access to Electronic Medical Records
10. Lilly Diabetes Announces Once Upon A Time Contest Winner
11. Roche announces FDA approval of HIV viral load test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/10/2017)... , Aug. 10, 2017  Physical Rehabilitation Network (PRN), acquired ... Lakewood, Colorado . The reputable clinic will ... , PT, DPT with his staff of four clinicians. Lipkin ... Pittsburgh and brings over 10 years of experience with a ... Belmar PT marks the 10th PRN clinic in and around ...
(Date:8/8/2017)...   Second-quarter 2017 ... loss per share from continuing operations ... 16 percent to $110 million ... to $161 million Second-quarter ... operations increased 8 percent to $0.93 ...
(Date:8/7/2017)... , Aug. 7, 2017 Zimmer Biomet Holdings, ... healthcare, today announced that its Board of Directors has approved ... the third quarter of 2017. ... paid on or about October 27, 2017 to stockholders of ... 2017.  Future declarations of dividends are subject to approval of ...
Breaking Medicine Technology:
(Date:8/24/2017)... ... August 24, 2017 , ... Prime candidates for home care ... a condition that needs further monitoring such as surgery, stroke, heart attack or ... such as diabetes, high blood pressure, heart/lung disease, arthritis and stroke. , ...
(Date:8/24/2017)... ... August 24, 2017 , ... DrinkingTutors.com, a startup focused on ... tutorials, or ‘drinktorials,’ are mailed directly to teenagers’ homes every week. , ... their teenagers avoid the serious risks associated with binge drinking in high school, ...
(Date:8/23/2017)... ... 2017 , ... This week the The Voss Law Firm celebrates 14 years ... the firm grew quickly and has built a reputation for excellence, trust, and accountability. ... money they deserve from their insurance companies. , The Voss Law Firm is ...
(Date:8/23/2017)... ... 23, 2017 , ... Earlier this month, the Workgroup for Electronic Data ... to create efficiencies in healthcare information exchange and a trusted advisor to the U.S. ... which featured keynote addresses by Donald W. Rucker, MD, head of the Office of ...
(Date:8/23/2017)... ... 2017 , ... The Stevie® Awards have announced the winners of the Best of the IBA ... awards competition. , Nominees in the 2017 IBAs were not able to apply for the ... the total number of awards won in the IBAs with a Gold Stevie win counting ...
Breaking Medicine News(10 mins):